Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)

NCT01595061 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT01595061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01595061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 2
Overall status
Unknown status
Start date
July 2, 2012
Completion date
September 23, 2022
Enrollment
57 (actual)
Sites
193

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii vulvar cancer ajcc v7, stage iiia vulvar cancer ajcc v7, stage iiib vulvar cancer ajcc v7, stage iiic vulvar cancer ajcc v7, stage iva vulvar cancer ajcc v7, vulvar squamous cell carcinoma